A5076321434- Hepatitis B Virus Studies
- Hepatitis C virus research
- SARS-CoV-2 and COVID-19 Research
- Hepatitis Viruses Studies and Epidemiology
- Vaccine Coverage and Hesitancy
- vaccines and immunoinformatics approaches
- Viral Infections and Outbreaks Research
- SARS-CoV-2 detection and testing
- COVID-19 and healthcare impacts
- COVID-19 Clinical Research Studies
- Intergenerational Family Dynamics and Caregiving
- Immunotherapy and Immune Responses
- Geriatric Care and Nursing Homes
- Immune responses and vaccinations
- Liver Disease Diagnosis and Treatment
- Infection Control and Ventilation
- Animal Virus Infections Studies
- Influenza Virus Research Studies
- T-cell and B-cell Immunology
- RNA Interference and Gene Delivery
- Dementia and Cognitive Impairment Research
- Cervical Cancer and HPV Research
- COVID-19 epidemiological studies
- Brucella: diagnosis, epidemiology, treatment
- Viral-associated cancers and disorders
John Radcliffe Hospital
2016-2024
University of Oxford
2016-2024
Oxford University Hospitals NHS Trust
2017-2024
Public Health England
2021
University of Massachusetts Dartmouth
2021
AbMax AntibodyChina (China)
2020
Murdoch University
1999
<ns4:p><ns4:bold>Background: </ns4:bold>Laboratory diagnosis of SARS-CoV-2 infection (the cause COVID-19) uses PCR to detect viral RNA (vRNA) in respiratory samples. has also been detected other sample types, but there is limited understanding the clinical or laboratory significance its detection blood.</ns4:p><ns4:p> <ns4:bold>Methods: </ns4:bold>We undertook a systematic literature review assimilate evidence for frequency vRNA blood, and identify associated characteristics. We performed...
<ns4:p><ns4:bold>Background: </ns4:bold>Laboratory diagnosis of SARS-CoV-2 infection (the cause COVID-19) uses PCR to detect viral RNA (vRNA) in respiratory samples. has also been detected other sample types, but there is limited understanding the clinical or laboratory significance its detection blood.</ns4:p><ns4:p> <ns4:bold>Methods: </ns4:bold>We undertook a systematic literature review assimilate evidence for frequency vRNA blood, and identify associated characteristics. We performed...
How human genetic variation contributes to vaccine effectiveness in infants is unclear, and data are limited on these relationships populations with African ancestries. We undertook analyses of antibody responses from Uganda (n = 1391), Burkina Faso 353) South Africa 755), identifying associations between leukocyte antigen (HLA) response for five eight tested antigens spanning pertussis, diphtheria hepatitis B vaccines. In addition, through HLA typing 1,702 individuals 11 ancestry derived...
In South Africa, the first HBV vaccine dose is administered at age 6 weeks, leaving a potential window for vertical transmission. Insights into seroprevalence in vulnerable HIV-infected group are important to drive improvements surveillance, treatment and prevention.We set out implement screening program among children adolescents Kimberley, Africa. Our aims were demonstrate that feasible sustainable, establish prevalence of HBV, characterise cases we identified, inform discussion about...
Sustainable Development Goals set a challenge for the elimination of hepatitis B virus (HBV) infection as public health concern by year 2030. Deployment robust prophylactic vaccine and enhanced interventions prevention mother to child transmission (PMTCT) are cornerstones strategy. However, in light estimated global burden 290 million cases, efforts required underpin optimisation Robust analysis population epidemiology is particularly crucial populations Africa made vulnerable HIV...
SARS-CoV-2 IgG screening of 1,000 antenatal serum samples in the Oxford area, United Kingdom, between 14 April and 15 June 2020, yielded a 5.3% seroprevalence, mirroring contemporaneous regional data. Among 53 positive samples, 39 showed vitro neutralisation activity, correlating with titre (Pearson’s correlation p<0.0001). While seroprevalence pregnancy cohorts could potentially inform population surveillance, clinical correlates infection immunity pregnancy, epidemiology evolution over...
Background: The seroprevalence of human parvovirus-4 (PARV4) varies considerably by region. In sub-Saharan Africa, is high in the general population, but little known about transmission routes or prevalence coinfection with blood-borne viruses, HBV, HCV and HIV. Methods: To further explore characteristics PARV4 this setting, a particular focus on significance coinfection, we screened cohort 695 individuals recruited from Durban Kimberley (South Africa) Gaborone (Botswana) for IgG DNA, as...
Abstract Introduction Current UK guidelines for cervical cancer screening are based on the assumption that most women living with HIV (WLWH) also high‐risk (HR) human papillomavirus (HPV)‐positive. We aimed to provide data prevalence of HR‐HPV in WLWH and assess feasibility acceptability self‐sampling this group. Methods Women attending six services London/south England, no history cancer, were enrolled. Participants self‐collected a vaginal swab detection HR‐HPV, completed survey about...
Hepatitis B virus (HBV) vaccine escape mutants (VEM) are increasingly described, threatening progress in control of this worldwide. Here we studied the relationship between host genetic variation, immunogenicity and viral sequences implicating VEM emergence. In a cohort 1,096 Bangladeshi children, identified human leukocyte antigen (HLA) variants associated with response antigens. Using an HLA imputation panel 9,448 south Asian individuals
Abstract How human genetic variation contributes to vaccine immunogenicity and effectiveness is unclear, particularly in infants from Africa. We undertook genome-wide association analyses of eight antibody responses 2,499 three African countries identified significant associations across the leukocyte antigen (HLA) locus for five antigens spanning pertussis, diphtheria hepatitis B vaccines. Using high-resolution HLA typing 1,706 individuals 11 populations we constructed a continental...
Introduction: Hepatitis B virus (HBV) infection is a pressing global public health threat, responsible for increasing mortality with disproportionate impact on populations in the WHO African region. There need evaluation of new biomarkers that may be able to provide insights into risk stratification and disease pathogenesis. We therefore set out evaluate core related antigen (HBcrAg), cohorts United Kingdom (UK) South Africa (SA). Methods: undertook cross-sectional retrospective...
Abstract Background: Sustainable Development Goals set a challenge for the elimination of hepatitis B virus (HBV) infection as public health concern by year 2030. Deployment robust prophylactic vaccine and enhanced interventions prevention mother to child transmission (PMTCT) are cornerstones strategy. However, in light estimated global burden 290 million cases, efforts required underpin optimisation Robust analysis population epidemiology is particularly crucial populations Africa made...